Les effets de la dépression

Un changement brutal de notre univers mental, de notre manière de faire monde avec ce qui nous entoure : c'est ce qui caractérise la dépression. Dans cette nouvelle saison de la collection de podcasts originaux “Votre cerveau”, Hugo Bottemanne, psychiatre à l'hôpital Bicêtre dans un centre spécialisé dans le traitement de la dépression; chercheur associé dans l'équipe Moods de l'Université Paris-Saclay et à l'Institut du cerveau de Paris, et co-auteur, avec Lucie Joly, de La dépression au féminin - Démystifier, comprendre, guérir (Le Rocher), nous aide à comprendre une maladie qui touche 350 millions de personnes.

Comment la dépression altère-t-elle les perceptions et les croyances ? Quelle est l'origine de ces biais de perception mais aussi des croyances négatives qui la caractérisent ? Car pour une personne dépressive, c’est en effet une transformation progressive et profonde de l’esprit qui se joue. On sait que chaque individu a une perception biaisée de la réalité mais avec la dépression, ce biais de perception est renforcé. À l’origine de ces croyances négatives, on observe la disparition d’un biais cognitif appelé “biais positif”, habituellement protecteur pour les individus.

Pour comprendre ce trouble, il est aussi capital de s’intéresser aux signaux corporels : ce qui transparaît dans votre pensée est aussi le reflet de ce qui se déroule à un niveau plus profond dans votre corps. Comment agissent les traitements anti-dépresseurs pour lutter contre la dépression et qu’augurent les médecines psychédéliques ?

Un podcast en 6 épisodes de 10 minutes, réalisé par Charlotte Roux, disponible le 6 novembre 2024 sur franceculture.fr et l’application Radio France

Une collection proposée par Camille Renard

Production : Hugo Bottemanne 
Réalisation : Charlotte Roux
Responsable des podcasts originaux : Camille Renard
Chargée de programmes : Élodie Piel
Prise de son : Delphine Baudet
Mixage : Anthony Thomasson, Inès de Bruyn

Avec la voix d’Aleksandra Wlodarczyk

À écouter

Traitement de la dépression : au revoir tristesse

La Science, CQFD

Écouter plus tard

Lecture

58 min

Bibliographie :

• Horwitz AG, Berona J, Czyz EK, Yeguez CE, King CA. Positive and Negative Expectations of Hopelessness as Longitudinal Predictors of Depression, Suicidal Ideation, and Suicidal Behavior in High-Risk Adolescents. Suicide Life Threat Behav. 2017 Apr;47(2):168–76.
• Eldar E, Rutledge RB, Dolan RJ, Niv Y. Mood as Representation of Momentum. Trends Cogn Sci. 2016 Jan;20(1):15–24.
• Beck AT. Thinking and depression : I. Idiosyncratic content and cognitive distortions. Archives of General Psychiatry. 1963;9(4):324–33.
• Philippi CL, Cornejo MD, Frost CP, Walsh EC, Hoks RM, Birn R, et al. Neural and behavioral correlates of negative self‐focused thought associated with depression. Hum Brain Mapp. 2018 Feb 9;39(5):2246–57.
• Andersen SM, Lyon JE. Anticipating undesired outcomes: The role of outcome certainty in the onset of depressive affect. Journal of Experimental Social Psychology. 1987;23(5):428–43.
• Stephan KE, Manjaly ZM, Mathys CD, Weber LAE, Paliwal S, Gard T, et al. Allostatic Self-efficacy: A Metacognitive Theory of Dyshomeostasis-Induced Fatigue and Depression. Front Hum Neurosci. 2016 Nov 15.
• Strunk DR, Lopez H, DeRubeis RJ. Depressive symptoms are associated with unrealistic negative predictions of future life events. Behav Res Ther. 2006 Jun;44(6):861–82.
• Miranda R, Fontes M, Marroquín B. Cognitive content-specificity in future expectancies: role of hopelessness and intolerance of uncertainty in depression and GAD symptoms. Behav Res Ther. 2008 Oct;46(10):1151–9.
• Hohwy J. The Predictive Mind. Oxford University Press, Oxford, 2013. ISBN: 978-0-19-968273-7.
• Bottemanne H, Longuet Y, Gauld C. The Predictive Mind: introduction to bayesian brain theory. L’Encephale. 2021.
• De Lange FP, Heilbron M, Kok P. How Do Expectations Shape Perception? Trends Cogn Sci. 2018.
• Clark A. Surfing Uncertainty: Prediction, Action, and the Embodied Mind. Oxford University Press. 2015.
• Friston KJ, FitzGerald T, Rigoli F. Active inference: a process theory. Neural Comput. 2016.
• Kube T, Rief W, Gollwitzer M, Gärtner T, Glombiewski JA. Why dysfunctional expectations in depression persist - Results from two experimental studies investigating cognitive immunization. Psychol Med. 2019;49(9):1532–44.
• Kube T, Kirchner L, Rief W, Gärtner T, Glombiewski JA. Belief updating in depression is not related to increased sensitivity to unexpectedly negative information. Behav Res Ther. 2019;123:103509.
• Everaert J, Bronstein MV, Cannon TD, Joormann J. Looking Through Tinted Glasses: Depression and Social Anxiety Are Related to Both Interpretation Biases and Inflexible Negative Interpretations. Clinical Psychological Science. 2018 Jul;6(4):517–28.
• Huntley CD, Fisher PL. Examining the role of positive and negative metacognitive beliefs in depression. Scand J Psychol. 2016 Oct;57(5):446–52.
• Hesp C, Smith R, Parr T, Allen M, Friston KJ, Ramstead MJD. Deeply Felt Affect: The Emergence of Valence in Deep Active Inference. Neural Comput. 2020 Nov 30;1–49.
• Sharot T, Korn CW, Dolan RJ. How unrealistic optimism is maintained in the face of reality. Nat Neurosci. 2011 Oct 9;14(11):1475–9.
• Kuzmanovic B, Rigoux L, Tittgemeyer M. Influence of vmPFC on dmPFC Predicts Valence-Guided Belief Formation. J Neurosci. 2018 12;38(37):7996–8010.
• Garrett N, Sharot T, Faulkner P, Korn CW, Roiser JP, Dolan RJ. Losing the rose tinted glasses: neural substrates of unbiased belief updating in depression. Front Hum Neurosci. 2014 Aug 28;8.
• Korn CW, Sharot T, Walter H, Heekeren HR, Dolan RJ. Depression is related to an absence of optimistically biased belief updating about future life events. Psychol Med. 2014 Feb;44(3):579–92.
• Robinson OJ, Chase HW. Learning and Choice in Mood Disorders: Searching for the Computational Parameters of Anhedonia. Comput Psychiatr. 2017;1(1):208–33.
• Lemogne C, le Bastard G, Mayberg H, Volle E, Bergouignan L, Lehéricy S, et al. In search of the depressive self: extended medial prefrontal network during self-referential processing in major depression. Soc Cogn Affect Neurosci. 2009 Sep;4(3):305–12.
• Garrett N, González-Garzón AM, Foulkes L, Levita L, Sharot T. Updating Beliefs under Perceived Threat. J Neurosci. 2018 Sep 5;38(36):7901–11.
• Koster EHW, De Lissnyder E, Derakshan N, De Raedt R. Understanding depressive rumination from a cognitive science perspective: the impaired disengagement hypothesis. Clin Psychol Rev. 2011 Feb;31(1):138–45.
• Takano K, Van Grieken J, Raes F. Difficulty in updating positive beliefs about negative cognition is associated with increased depressed mood. J Behav Ther Exp Psychiatry. 2019;64:22–30.
• Brown EC, Brüne M. The role of prediction in social neuroscience. Front Hum Neurosci. 2012;6:147.
• Andersen SM, Spielman LA, Bargh JA. Future-event schemas and certainty about the future: Automaticity in depressives’ future-event predictions. Journal of Personality and Social Psychology. 1992;63(5):711–23.
• Andersen SM, Lyon JE. Anticipating undesired outcomes: The role of outcome certainty in the onset of depressive affect. Journal of Experimental Social Psychology. 1987;23(5):428–43.
• Pyszczynski T, Holt K, Greenberg J. Depression, self-focused attention, and expectancies for positive and negative future life events for self and others. Journal of Personality and Social Psychology. 1987;52(5):994–1001.
• Alloy LB, Ahrens AH. Depression and pessimism for the future: biased use of statistically relevant information in predictions for self versus others. J Pers Soc Psychol. 1987 Feb;52(2):366–78.
• Horwitz AG, Berona J, Czyz EK, Yeguez CE, King CA. Positive and Negative Expectations of Hopelessness as Longitudinal Predictors of Depression, Suicidal Ideation, and Suicidal Behavior in High-Risk Adolescents. Suicide Life Threat Behav. 2017 Apr;47(2):168–76.
• Strunk DR, Lopez H, DeRubeis RJ. Depressive symptoms are associated with unrealistic negative predictions of future life events. Behav Res Ther. 2006 Jun;44(6):861–82.
• Herwig U, Brühl AB, Kaffenberger T, Baumgartner T, Boeker H, Jäncke L. Neural correlates of “pessimistic” attitude in depression. Psychol Med. 2010 May;40(5):789–800.
• Wenze SJ, Gunthert KC, German RE. Biases in affective forecasting and recall in individuals with depression and anxiety symptoms. Pers Soc Psychol Bull. 2012 Jul;38(7):895–906.
• Miranda R, Fontes M, Marroquín B. Cognitive content-specificity in future expectancies: role of hopelessness and intolerance of uncertainty in depression and GAD symptoms. Behav Res Ther. 2008 Oct;46(10):1151–9.
• MacLeod AK, Salaminiou E. Reduced positive future-thinking in depression: Cognitive and affective factors. Cognition and Emotion. 2001;15(1):99–107.
• Wisco BE. Depressive cognition: self-reference and depth of processing. Clin Psychol Rev. 2009 Jun;29(4):382–92.
• Lewandowsky S, Ecker UKH, Seifert CM, Schwarz N, Cook J. Misinformation and Its Correction: Continued Influence and Successful Debiasing. Psychol Sci Public Interest. 2012 Dec;13(3):106–31.
• Cook J, Lewandowsky S. Rational Irrationality: Modeling Climate Change Belief Polarization Using Bayesian Networks. Topics in Cognitive Science. 2016;8(1):160–79.
• Lewandowsky S, Cook J, Lloyd E. The ‘Alice in Wonderland’ mechanics of the rejection of (climate) science: simulating coherence by conspiracism. Synthese. 2018 Jan 1;195(1):175–96.
• Nyhan B, Reifler J. When corrections fail: The persistence of political misperceptions. Political Behavior. 2010;32(2):303–30.
• Collins PJ, Hahn U, von Gerber Y, Olsson EJ. The Bi-directional Relationship between Source Characteristics and Message Content. Front Psychol. 2018;9:18.
• Hohwy J. The Predictive Mind. Oxford University Press, Oxford, 2013. ISBN: 978-0-19-968273-7.
• Huntley CD, Fisher PL. Examining the role of positive and negative metacognitive beliefs in depression. Scand J Psychol. 2016 Oct;57(5):446–52.
• Keefe JR, Webb CA, DeRubeis RJ. In Cognitive Therapy for Depression, Early Focus on Maladaptive Beliefs May Be Especially Efficacious for Patients with Personality Disorders. J Consult Clin Psychol. 2016 Apr;84(4):353–64.
• Sharot T, Korn CW, Dolan RJ. How unrealistic optimism is maintained in the face of reality. Nat Neurosci. 2011 Oct 9;14(11):1475–9.
• Kuzmanovic B, Rigoux L, Tittgemeyer M. Influence of vmPFC on dmPFC Predicts Valence-Guided Belief Formation. J Neurosci. 2018 12;38(37):7996–8010.
• De Raedt R, Koster EHW. Understanding vulnerability for depression from a cognitive neuroscience perspective: A reappraisal of attentional factors and a new conceptual framework. Cogn Affect Behav Neurosci. 2010 Mar;10(1):50–70.
• Everaert J, Podina IR, Koster EHW. A comprehensive meta-analysis of interpretation biases in depression. Clin Psychol Rev. 2017 Dec;58:33–48.
• Dalgleish T, Watts FN. Biases of attention and memory in disorders of anxiety and depression. Clinical Psychology Review. 1990;10(5):589–604.
• Bistricky SL, Ingram RE, Atchley RA. Facial affect processing and depression susceptibility: cognitive biases and cognitive neuroscience. Psychol Bull. 2011 Nov;137(6):998–1028.
• Gotlib IH, Krasnoperova E, Yue DN, Joormann J. Attentional biases for negative interpersonal stimuli in clinical depression. J Abnorm Psychol. 2004 Feb;113(1):121–35.
• Foland-Ross LC, Gotlib IH. Cognitive and neural aspects of information processing in major depressive disorder: an integrative perspective. Front Psychol. 2012;3:489.
• Lemogne C, le Bastard G, Mayberg H, Volle E, Bergouignan L, Lehéricy S, et al. In search of the depressive self: extended medial prefrontal network during self-referential processing in major depression. Soc Cogn Affect Neurosci. 2009 Sep;4(3):305–12.
• Sass K, Habel U, Kellermann T, Mathiak K, Gauggel S, Kircher T. The influence of positive and negative emotional associations on semantic processing in depression: an fMRI study. Hum Brain Mapp. 2014 Feb;35(2):471–82.
• Lemos JC, Wanat MJ, Smith JS, Reyes BAS, Hollon NG, Van Bockstaele EJ, et al. Severe stress switches CRF action in the nucleus accumbens from appetitive to aversive. Nature. 2012 Oct 18;490(7420):402–6.
• Marroquín B, Nolen-Hoeksema S. Emotion regulation and depressive symptoms: Close relationships as social context and influence. Journal of Personality and Social Psychology. 2015;109(5):836–55.
• Takano K, Van Grieken J, Raes F. Difficulty in updating positive beliefs about negative cognition is associated with increased depressed mood. J Behav Ther Exp Psychiatry. 2019;64:22–30.
• Matsumoto N, Mochizuki S. Why do People Overthink? A Longitudinal Investigation of a Meta-Cognitive Model and Uncontrollability of Rumination. Behav Cogn Psychother. 2018 Jul;46(4):504–9.
• Yilmaz AE, Gençöz T, Wells A. Unique contributions of metacognition and cognition to depressive symptoms. J Gen Psychol. 2015;142(1):23–33.
• LaGrange B, Cole DA, Jacquez F, Ciesla J, Dallaire D, Pineda A, et al. Disentangling the Prospective Relations Between Maladaptive Cognitions and Depressive Symptoms. J Abnorm Psychol. 2011 Aug;120(3):511–27.
• Aan Het Rot, M., Zarate, C. A., Charney, D. S., & Mathew, S. J. (2012). Ketamine for depression: Where do we go from here? Biological Psychiatry, 72(7), 537–547.
• Agin-Liebes, G., Haas, T. F., Lancelotta, R., Uthaug, M. V., Ramaekers, J. G., & Davis, A. K. (2021). Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes. ACS Pharmacology & Translational Science, 4(2), 543–552.
• Aleksandrova, L. R., & Phillips, A. G. (2021). Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics. Trends in Pharmacological Sciences, 42(11), 929–942.
• Bahji, A., Vazquez, G. H., & Zarate, C. A. (2021). Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. Journal of Affective Disorders, 278, 542–555.
• Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000). Antidepressant effects of ketamine in depressed patients. Biological Psychiatry, 47(4), 351–354.
• Bottemanne, H., Baldacci, A., Muller, C., Boyreau, A., & Claret, A. (2021). Ketamine Augmented Psychotherapy (KAP) in mood disorder: User guide. L’Encephale, S0013-7006(21)00224-4.
• Bottemanne, H., Berkovitch, L., Gauld, C., Balcerac, A., Schmidt, L., Mouchabac, S., & Fossati, P. (2023). Storm on predictive brain: A neurocomputational account of ketamine antidepressant effect. Neuroscience and Biobehavioral Reviews, 105410.
• Bottemanne, H., Claret, A., & Fossati, P. (2021). Ketamine, psilocybin, and rapid acting antidepressant: New promise for psychiatry?. L’Encephale, 47(2), 171–178.
• Bottemanne, H., Morlaàs, O., Claret, A., Fossati, P., & Schmidt, L. (2022). Changing depressive beliefs: An observational study of early ketamine effects on belief updating biases in treatment-resistant depression. JAMA Psychiatry.
• Calder, A. E., & Hasler, G. (2022). Towards an understanding of psychedelic-induced neuroplasticity. Neuropsychopharmacology, 1–9.
• Calvey, T., & Howells, F. M. (2018). An introduction to psychedelic neuroscience. Progress in Brain Research, 242, 1–23.
• Cameron, L. P., Tombari, R. J., Lu, J., Pell, A. J., Hurley, Z. Q., Ehinger, Y., Vargas, M. V., McCarroll, M. N., Taylor, J. C., Myers-Turnbull, D., Liu, T., Yaghoobi, B., Laskowski, L. J., Anderson, E. I., Zhang, G., Viswanathan, J., Brown, B. M., Tjia, M., Dunlap, L. E., … Olson, D. E. (2021). A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature, 589(7842), Article 7842.
• Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. The New England Journal of Medicine, 384(15), 1402–1411.
• Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Curran, H. V., & Nutt, D. J. (2018). Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up. Psychopharmacology, 235(2), 399–408.
• Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Pilling, S., Curran, V. H., & Nutt, D. J. (2016). Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. The Lancet. Psychiatry, 3(7), 619–627.
• Carhart-Harris, R. L., & Friston, K. J. (2019). REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics. Pharmacological Reviews, 71(3), 316–344.
• Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M. (2018). Psychedelics and the essential importance of context. Journal of Psychopharmacology (Oxford, England), 32(7), 725–731.
• Daly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., & Drevets, W. C. (2018). Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry, 75(2), 139–148.
• Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2020). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry.
• Dean, R. L., Marquardt, T., Hurducas, C., Spyridi, S., Barnes, A., Smith, R., Cowen, P. J., McShane, R., Hawton, K., Malhi, G. S., Geddes, J., & Cipriani, A. (2021). Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder. The Cochrane Database of Systematic Reviews, 10(10), CD011611.
• Díaz, J. L. (1977). Ethnopharmacology of sacred psychoactive plants used by the Indians of Mexico. Annual Review of Pharmacology and Toxicology, 17, 647–675.
• Fava, M., Freeman, M. P., Flynn, M., Judge, H., Hoeppner, B. B., Cusin, C., Ionescu, D. F., Mathew, S. J., Chang, L. C., Iosifescu, D. V., Murrough, J., Debattista, C., Schatzberg, A. F., Trivedi, M. H., Jha, M. K., Sanacora, G., Wilkinson, S. T., & Papakostas, G. I. (2020). Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Molecular Psychiatry, 25(7), 1592–1603.
• Friston, K. (2005). A theory of cortical responses. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, 360(1456), 815–836.
• Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014). Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. The Journal of Nervous and Mental Disease, 202(7), 513–520.
• Goldberg, S. B., Pace, B. T., Nicholas, C. R., Raison, C. L., & Hutson, P. R. (2020). The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. Psychiatry Research, 284, 112749.
• Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., … Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637–1648.
• Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology (Oxford, England), 30(12), 1181–1197.
• Han, Y., Chen, J., Zou, D., Zheng, P., Li, Q., Wang, H., Li, P., Zhou, X., Zhang, Y., Liu, Y., & Xie, P. (2016). Efficacy of ketamine in the rapid treatment of major depressive disorder: A meta-analysis of randomized, double-blind, placebo-controlled studies. Neuropsychiatric Disease and Treatment, 12, 2859–2867.
• Harraz, M. M., Tyagi, R., Cortés, P., & Snyder, S. H. (2016). Antidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradation. Molecular Psychiatry, 21(3), 313–319.
• Holze, F., Gasser, P., Müller, F., Dolder, P. C., & Liechti, M. E. (2023). Lysergic Acid Diethylamide–Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study. Biological Psychiatry, 93(3), 215–223.
• Johnson, M., Richards, W., & Griffiths, R. (2008). Human hallucinogen research: Guidelines for safety. Journal of Psychopharmacology (Oxford, England), 22(6), 603–620.
• Kometer, M., Schmidt, A., Jäncke, L., & Vollenweider, F. X. (2013). Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 33(25), 10544–10551.
• Mason, N. L., Kuypers, K. P. C., Müller, F., Reckweg, J., Tse, D. H. Y., Toennes, S. W., Hutten, N. R. P. W., Jansen, J. F. A., Stiers, P., Feilding, A., & Ramaekers, J. G. (2020). Me, myself, bye: Regional alterations in glutamate and the experience of ego dissolution with psilocybin. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 45(12), 2003–2011.
• Miller, M. J., Albarracin-Jordan, J., Moore, C., & Capriles, J. M. (2019). Chemical evidence for the use of multiple psychotropic plants in a 1,000-year-old ritual bundle from South America. Proceedings of the National Academy of Sciences of the United States of America, 116(23), 11207–11212.
• Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot’alora G, M., Garas, W., Paleos, C., Gorman, I., Nicholas, C., Mithoefer, M., Carlin, S., Poulter, B., Mithoefer, A., Quevedo, S., Wells, G., Klaire, S. S., van der Kolk, B., … Doblin, R. (2021). MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, 27(6), 1025–1033.
• Mitchell, J. M., Ot’alora G., M., van der Kolk, B., Shannon, S., Bogenschutz, M., Gelfand, Y., Paleos, C., Nicholas, C. R., Quevedo, S., Balliett, B., Hamilton, S., Mithoefer, M., Kleiman, S., Parker-Guilbert, K., Tzarfaty, K., Harrison, C., de Boer, A., Doblin, R., & Yazar-Klosinski, B. (2023). MDMA-assisted therapy for moderate to severe PTSD: A randomized, placebo-controlled phase 3 trial. Nature Medicine, 1–8.
• Moliner, R., Girych, M., Brunello, C. A., Kovaleva, V., Biojone, C., Enkavi, G., Antenucci, L., Kot, E. F., Goncharuk, S. A., Kaurinkoski, K., Kuutti, M., Fred, S. M., Elsilä, L. V., Sakson, S., Cannarozzo, C., Diniz, C. R. A. F., Seiffert, N., Rubiolo, A., Haapaniemi, H., … Castrén, E. (2023). Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nature Neuroscience, 26(6), Article 6.
• Muetzelfeldt, L., Kamboj, S. K., Rees, H., Taylor, J., Morgan, C. J. A., & Curran, H. V. (2008). Journey through the K-hole: Phenomenological aspects of ketamine use. Drug and Alcohol Dependence, 95(3), 219–229.
• Nour, M. M., Evans, L., Nutt, D., & Carhart-Harris, R. L. (2016). Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI). Frontiers in Human Neuroscience, 10, 269.
• Nutt, D., & Carhart-Harris, R. (2021). The Current Status of Psychedelics in Psychiatry. JAMA Psychiatry, 78(2), 121–122.
• Osório, F. de L., Sanches, R. F., Macedo, L. R., Santos, R. G. dos, Maia-de-Oliveira, J. P., Wichert-Ana, L., Araujo, D. B. de, Riba, J., Crippa, J. A., & Hallak, J. E. (2015). Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A preliminary report. Revista Brasileira De Psiquiatria (Sao Paulo, Brazil: 1999), 37(1), 13–20.
• Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., Dos Santos, R. G., Tófoli, L. F., de Oliveira Silveira, G., Yonamine, M., Riba, J., Santos, F. R., Silva-Junior, A. A., Alchieri, J. C., Galvão-Coelho, N. L., Lobão-Soares, B., … Araújo, D. B. (2019). Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial. Psychological Medicine, 49(4), 655–663.
• Perry, E. B., Cramer, J. A., Cho, H.-S., Petrakis, I. L., Karper, L. P., Genovese, A., O’Donnell, E., Krystal, J. H., D’Souza, D. C., & Yale Ketamine Study Group. (2007). Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology, 192(2), 253–260.
• Preller, K. H., & Vollenweider, F. X. (2018). Phenomenology, Structure, and Dynamic of Psychedelic States. In A. L. Halberstadt, F. X. Vollenweider, & D. E. Nichols (Eds.), Behavioral Neurobiology of Psychedelic Drugs (pp. 221–256). Springer.
• Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., … Griffiths, R. R. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 330(9), 843–853.
• Reckweg, J. T., van Leeuwen, C. J., Henquet, C., van Amelsvoort, T., Theunissen, E. L., Mason, N. L., Paci, R., Terwey, T. H., & Ramaekers, J. G. (2023). A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression. Frontiers in Psychiatry, 14.
• Romeo, B., Choucha, W., Fossati, P., & Rotge, J.-Y. (2015). Meta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression. Psychiatry Research, 230(2), 682–688.
• Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology (Oxford, England), 30(12), 1165–1180.
• Rucker, J. J., Jelen, L. A., Flynn, S., Frowde, K. D., & Young, A. H. (2016). Psychedelics in the treatment of unipolar mood disorders: A systematic review. Journal of Psychopharmacology (Oxford, England), 30(12), 1220–1229.
• Rybak, Y. E., Lai, K. S. P., Ramasubbu, R., Vila‐Rodriguez, F., Blumberger, D. M., Chan, P., Delva, N., Giacobbe, P., Gosselin, C., Kennedy, S. H., Iskandar, H., McInerney, S., Ravitz, P., Sharma, V., Zaretsky, A., & Burhan, A. M. (2021). Treatment-resistant major depressive disorder: Canadian expert consensus on definition and assessment. Depression and Anxiety, 38(4), 456–467.
• Sanches, R. F., de Lima Osório, F., Dos Santos, R. G., Macedo, L. R. H., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A. S., & Hallak, J. E. C. (2016). Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study. Journal of Clinical Psychopharmacology, 36(1), 77–81.
• Swainson, J., McGirr, A., Blier, P., Brietzke, E., Richard-Devantoy, S., Ravindran, N., Blier, J., Beaulieu, S., Frey, B. N., Kennedy, S. H., McIntyre, R. S., Milev, R. V., Parikh, S. V., Schaffer, A., Taylor, V. H., Tourjman, V., van Ameringen, M., Yatham, L. N., Ravindran, A. V., & Lam, R. W. (2021). The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L’humeur Et De L’anxiété (Canmat) Concernant L’utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie, 66(2), 113–125.
• Tang, J., Xue, W., Xia, B., Ren, L., Tao, W., Chen, C., Zhang, H., Wu, R., Wang, Q., Wu, H., Duan, J., & Chen, G. (2015). Involvement of normalized NMDA receptor and mTOR-related signaling in rapid antidepressant effects of Yueju and ketamine on chronically stressed mice. Scientific Reports, 5, 13573.
• Vollenweider, F. X., & Kometer, M. (2010). The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders. Nature Reviews. Neuroscience, 11(9), 642–651.
• Von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56, 101809.
• Watts, R., & Luoma, J. B. (2020). The use of the psychological flexibility model to support psychedelic assisted therapy. Journal of Contextual Behavioral Science, 15, 92–102.
• World Health Organization. Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: World Health Organization; 2017. (n.d.).
• Xiong, J., Lipsitz, O., Chen-Li, D., Rosenblat, J. D., Rodrigues, N. B., Carvalho, I., Lui, L. M. W., Gill, H., Narsi, F., Mansur, R. B., Lee, Y., & McIntyre, R. S. (2021). The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis. Journal of Psychiatric Research, 134, 57–68.